Kiliana Suzart-Woischnik

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Atrial Fibrillation

Clinical Practice

Top Venues

Expert opinion on drug safety

Drugs - real world outcomes

This page only lists publications with an associated author ORCID identifier.

Publications

Gunnar Brobert, Ana Ruigomez, Cristina Rebordosa, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin M A Swart, Leif Friberg, Yanina Balabanova, Christine Tarenz, Kiliana Suzart-Woischnik, Montse Soriano Gabarró, Pareen Vora, Martin Homering, Tomasz Dyszynski, Gerd Nagel, Pablo Amaya, Luis Alberto García-Rodríguez
Challenges and lessons learned from a long-term postauthorisation safety study programme of rivaroxaban in Europe. BMJ open 14 (3) (2024)
Gunnar Brobert, Ana Ruigomez, Cristina Rebordosa, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin M A Swart, Leif Friberg, Yanina Balabanova, Christine Tarenz, Kiliana Suzart-Woischnik, Montse Soriano Gabarró, Pareen Vora, Martin Homering, Tomasz Dyszynski, Gerd Nagel, Pablo Amaya, Luis Alberto García-Rodríguez
Challenges and lessons learned from a long-term postauthorisation safety study programme of rivaroxaban in Europe. BMJ open 14 (3) (2024)
Gunnar Brobert, Ana Ruigomez, Cristina Rebordosa, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin M A Swart, Leif Friberg, Yanina Balabanova, Christine Tarenz, Kiliana Suzart-Woischnik, Montse Soriano Gabarró, Pareen Vora, Martin Homering, Tomasz Dyszynski, Gerd Nagel, Pablo Amaya, Luis Alberto García-Rodríguez
Challenges and lessons learned from a long-term postauthorisation safety study programme of rivaroxaban in Europe. BMJ open 14 (3) (2024)
Gunnar Brobert, Ana Ruigomez, Cristina Rebordosa, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin M A Swart, Leif Friberg, Yanina Balabanova, Christine Tarenz, Kiliana Suzart-Woischnik, Montse Soriano Gabarró, Pareen Vora, Martin Homering, Tomasz Dyszynski, Gerd Nagel, Pablo Amaya, Luis Alberto García-Rodríguez
Challenges and lessons learned from a long-term postauthorisation safety study programme of rivaroxaban in Europe. BMJ open 14 (3) (2024)
Luis Alberto García-Rodríguez, Ana Ruigómez, Cristina Rebordosa, Annemarie Voss, Elisabeth Smits, Karin M A Swart, Yanina Balabanova, Kiliana Suzart-Woischnik, Gunnar Brobert, Ron M C Herings
Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries. Expert opinion on drug safety (2023)
Annemarie Voss, Elisabeth Smits, Karin M A Swart, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Ron M C Herings, Cristina Rebordosa, Ulrike Haug
Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands. Drugs - real world outcomes (2023)
Laurie Zografos, Dan Wolin, Elizabeth Andrews, Brian Calingaert, Yanina Balabanova, Andrea Horvat-Bröcker, Christine Tarenz, Kiliana Suzart-Woischnik
Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries. Expert opinion on drug safety (2021)
Luis Alberto García-Rodríguez, Mari-Ann Wallander, Leif Friberg, Ana Ruigómez, Cristina Rebordosa, Irene D Bezemer, Ron M C Herings, Saad Shakir, Alison Evans, Miranda Davies, Kiliana Suzart-Woischnik, Pareen Vora, Yanina Balabanova, Montse Soriano Gabarró, Gunnar Brobert
Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice. Expert opinion on drug safety 19 (11) (2020)